News articles about Regeneron Pharmaceuticals (NASDAQ:REGN) have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.857094404723 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Regeneron Pharmaceuticals Inc (REGN) Given Average Rating of “Hold” by Analysts (americanbankingnews.com)
- Regeneron and Sanofi Plan to Cut Cholesterol Drug Price in … – Wall Street Journal (wsj.com)
- UPDATE 1-Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay? (feeds.reuters.com)
- Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate (finance.yahoo.com)
Shares of Regeneron Pharmaceuticals (REGN) traded up $0.92 during trading on Friday, reaching $341.70. 758,069 shares of the company were exchanged, compared to its average volume of 1,140,000. The stock has a market cap of $36,810.00, a price-to-earnings ratio of 26.00, a PEG ratio of 1.07 and a beta of 1.54. Regeneron Pharmaceuticals has a 1 year low of $313.53 and a 1 year high of $543.55. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18.
Several brokerages have weighed in on REGN. ValuEngine downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Canaccord Genuity downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price target for the stock from $522.00 to $356.00 in a research report on Wednesday, February 21st. Zacks Investment Research raised Regeneron Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $380.00 price target on the stock in a research report on Friday, February 16th. BTIG Research reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, February 13th. Finally, SunTrust Banks set a $430.00 price target on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, February 9th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $450.65.
In related news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total value of $325,600.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 10.80% of the company’s stock.
WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Regeneron Pharmaceuticals (REGN) Share Price” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3254140/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-regeneron-pharmaceuticals-regn-share-price.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.